News
The GLP-1 Pill War Has a Clear Early Winner and It Isn't Lilly
Novo Nordisk's Wegovy pill generated $354 million in its first full quarter on the market, nearly double analyst expectations. The company now has a commanding early lead in the oral GLP-1 market over Eli Lilly's Foundayo.